Aartsma-Rus A - Search Results

1

Splice modulating therapies for human disease.

Spitali P, Aartsma-Rus A. Spitali P, et al. Cell. 2012 Mar 16;148(6):1085-8. doi: 10.1016/j.cell.2012.02.014. Cell. 2012. PMID: 22424220 Review.

2

Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.

Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC. Aartsma-Rus A, et al. Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7. doi: 10.1016/s0960-8966(02)00086-x. Neuromuscul Disord. 2002. PMID: 12206800

3

Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.

Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC. Aartsma-Rus A, et al. Hum Mol Genet. 2003 Apr 15;12(8):907-14. doi: 10.1093/hmg/ddg100. Hum Mol Genet. 2003. PMID: 12668614

4

Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.

Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC. Aartsma-Rus A, et al. Am J Hum Genet. 2004 Jan;74(1):83-92. doi: 10.1086/381039. Epub 2003 Dec 16. Am J Hum Genet. 2004. PMID: 14681829 Free PMC article.

5

Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.

Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC. Aartsma-Rus A, et al. Gene Ther. 2004 Sep;11(18):1391-8. doi: 10.1038/sj.gt.3302313. Gene Ther. 2004. PMID: 15229633

6

Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides.

Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, Vossen RH, van Ommen GJ, den Dunnen JT, van Deutekom JC. Bremmer-Bout M, et al. Mol Ther. 2004 Aug;10(2):232-40. doi: 10.1016/j.ymthe.2004.05.031. Mol Ther. 2004. PMID: 15294170

7

Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites.

Aartsma-Rus A, De Winter CL, Janson AA, Kaman WE, Van Ommen GJ, Den Dunnen JT, Van Deutekom JC. Aartsma-Rus A, et al. Oligonucleotides. 2005 Dec;15(4):284-97. doi: 10.1089/oli.2005.15.284. Oligonucleotides. 2005. PMID: 16396622

8

Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy.

't Hoen PA, van der Wees CG, Aartsma-Rus A, Turk R, Goyenvalle A, Danos O, Garcia L, van Ommen GJ, den Dunnen JT, van Deutekom JC. 't Hoen PA, et al. Pharmacogenomics. 2006 Apr;7(3):281-97. doi: 10.2217/14622416.7.3.281. Pharmacogenomics. 2006. PMID: 16610940

9

Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.

Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC. Aartsma-Rus A, et al. Mol Ther. 2006 Sep;14(3):401-7. doi: 10.1016/j.ymthe.2006.02.022. Epub 2006 Jun 6. Mol Ther. 2006. PMID: 16753346

10

Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule.

Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Aartsma-Rus A, et al. Muscle Nerve. 2006 Aug;34(2):135-44. doi: 10.1002/mus.20586. Muscle Nerve. 2006. PMID: 16770791 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results